Dexrazoxane may alter anthracycline pharmacokinetics and potentially reduce anticancer efficacy if used early [43], while ACE inhibitors/ARNIs may increase the risk of hypotension or renal dysfunction when used with VEGF inhibitors [44]. The gene discussed is ACE; the disease is Abnormal renal physiology.